Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:BLTENASDAQ:IDYAOTCMKTS:TRUU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$34.30-0.6%$29.76$23.42▼$62.58$1.99B0.73662,530 shs478,627 shsBLTEBelite Bio$59.55-4.2%$61.01$43.70▼$86.53$1.90B-1.4447,349 shs21,092 shsIDYAIDEAYA Biosciences$22.18-0.4%$18.94$13.45▼$44.42$1.94B0.041.03 million shs862,850 shsTRUUTrue Drinks$0.10-7.9%$0.09$0.00▼$0.08$498.26M10.91.01 million shs21,732 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-0.09%+21.37%+10.90%-28.50%BLTEBelite Bio0.00%-0.22%-11.21%-11.70%+19.16%IDYAIDEAYA Biosciences0.00%+2.07%+28.13%+19.38%-43.72%TRUUTrue Drinks-7.90%-6.14%+13.63%+128.25%-28.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals3.9345 of 5 stars3.41.00.04.21.80.81.9BLTEBelite Bio2.7956 of 5 stars3.53.00.00.03.90.80.6IDYAIDEAYA Biosciences3.851 of 5 stars3.52.00.04.42.81.70.0TRUUTrue DrinksN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6070.85% UpsideBLTEBelite Bio 3.00Buy$96.6762.33% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27144.69% UpsideTRUUTrue Drinks 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRUU, IDYA, BLTE, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.003/26/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/18/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M53.64N/AN/A$27.02 per share1.27BLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/AIDYAIDEAYA Biosciences$7M277.51N/AN/A$12.10 per share1.83TRUUTrue Drinks$1.95M255.52N/AN/A($0.03) per share-3.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.02N/AN/A1,845.92%-2.51%-2.26%7/30/2025 (Estimated)BLTEBelite Bio-$31.63M-$1.36N/AN/AN/AN/A-31.94%-30.73%8/8/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.0110.02∞N/A-255.80%N/A-165.86%N/ALatest TRUU, IDYA, BLTE, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56BLTEBelite BioN/A30.7330.73IDYAIDEAYA BiosciencesN/A14.9722.93TRUUTrue DrinksN/A0.01N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABLTEBelite Bio0.53%IDYAIDEAYA Biosciences98.29%TRUUTrue DrinksN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%BLTEBelite Bio13.29%IDYAIDEAYA Biosciences2.50%TRUUTrue Drinks18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableTRUUTrue Drinks404.97 billionN/ANot OptionableTRUU, IDYA, BLTE, and AGIO HeadlinesRecent News About These CompaniesTrue Drinks (OTCMKTS:TRUU) Stock Crosses Above Fifty Day Moving Average - Here's WhyJune 1, 2025 | marketbeat.comBeer News: True Acts Of Aletruism / New “Indie Beer” CampaignNovember 13, 2024 | americancraftbeer.comHow Much Alcohol Can You Drink a Week and Still Be Healthy?November 13, 2024 | msn.comStarbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional factsNovember 9, 2024 | msn.comCan You Drink Alcohol After Getting a COVID-19 Booster?October 29, 2024 | health.comIt's True: Some Pizza Hut Locations Still Serve AlcoholOctober 22, 2024 | yahoo.comReview: True Story Finished BourbonOctober 21, 2024 | msn.comVitalizes Body and Mind.®October 4, 2024 | redbull.com7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’October 2, 2024 | msn.com‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in itSeptember 21, 2024 | nypost.comSeattle’s True Loves Drop a Funky New SingleAugust 31, 2024 | msn.comCannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinksAugust 31, 2024 | msn.comThese alcoholic drinks can raise the risk of gout, a painful type of arthritisAugust 30, 2024 | nypost.com14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master MixologistAugust 29, 2024 | yahoo.com7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)August 25, 2024 | bbc.co.uk12 Unhealthiest Drinks You Should Think Twice About Ordering At A BarAugust 18, 2024 | msn.comTrue Loaf Bakery gets starter from two local bakersAugust 10, 2024 | msn.comPD TRUE : STREAM IT OR SKIP IT?August 6, 2024 | decider.com10 Drinks People Fake Liking to Fit InAugust 5, 2024 | msn.com16 Best Summer Cocktails for a Hot Weather BuzzJuly 26, 2024 | esquire.comWhat is ‘fluffy Coke’? Sugary drink dubbed ‘diabetes in a cup’ is the hottest beverage of the summerJuly 23, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRUU, IDYA, BLTE, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$34.30 -0.20 (-0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.31 +0.01 (+0.03%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Belite Bio NASDAQ:BLTE$59.55 -2.59 (-4.17%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$59.45 -0.10 (-0.17%) As of 06/13/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.IDEAYA Biosciences NASDAQ:IDYA$22.18 -0.10 (-0.45%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.96 -0.22 (-0.99%) As of 06/13/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.True Drinks OTCMKTS:TRUU$0.10 -0.01 (-7.90%) As of 06/13/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
